ONCY vs. AFMD, ETON, BTAI, CMRX, QTTB, PMVP, HOOK, YS, SPRO, and IFRX
Should you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include Affimed (AFMD), Eton Pharmaceuticals (ETON), BioXcel Therapeutics (BTAI), Chimerix (CMRX), Q32 Bio (QTTB), PMV Pharmaceuticals (PMVP), Hookipa Pharma (HOOK), YS Biopharma (YS), Spero Therapeutics (SPRO), and InflaRx (IFRX). These companies are all part of the "pharmaceutical preparations" industry.
Affimed (NASDAQ:AFMD) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, valuation and community ranking.
In the previous week, Affimed had 1 more articles in the media than Oncolytics Biotech. MarketBeat recorded 4 mentions for Affimed and 3 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 0.30 beat Affimed's score of 0.00 indicating that Affimed is being referred to more favorably in the media.
30.8% of Affimed shares are owned by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are owned by institutional investors. 3.8% of Affimed shares are owned by company insiders. Comparatively, 0.1% of Oncolytics Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Affimed has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500. Comparatively, Oncolytics Biotech has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500.
Affimed presently has a consensus price target of $45.00, suggesting a potential upside of 794.63%. Oncolytics Biotech has a consensus price target of $4.00, suggesting a potential upside of 266.97%. Given Oncolytics Biotech's higher probable upside, research analysts plainly believe Affimed is more favorable than Oncolytics Biotech.
Oncolytics Biotech has lower revenue, but higher earnings than Affimed. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Affimed, indicating that it is currently the more affordable of the two stocks.
Affimed received 278 more outperform votes than Oncolytics Biotech when rated by MarketBeat users. Likewise, 69.92% of users gave Affimed an outperform vote while only 68.16% of users gave Oncolytics Biotech an outperform vote.
Oncolytics Biotech has a net margin of 0.00% compared to Oncolytics Biotech's net margin of -1,280.27%. Affimed's return on equity of -105.97% beat Oncolytics Biotech's return on equity.
Summary
Affimed beats Oncolytics Biotech on 11 of the 16 factors compared between the two stocks.
Get Oncolytics Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ONCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncolytics Biotech Competitors List
Related Companies and Tools
